Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

TPIV 200

Vaccine (Peptide vaccine) · Immune activation, directed at folate receptor 1 (FR-alpha) (FOLR1) · developed by Marker Therapeutics

Phase 2 Most advanced trial (none active)
MRKR Developer
2 Registered trials

What is TPIV 200?

TPIV 200 is a peptide vaccine containing five immunogenic epitopes of folate receptor 1 (FR-alpha). Administered intradermally, it induces cytotoxic T-lymphocyte responses against FR-alpha-overexpressing tumor cells. It is studied in breast and ovarian cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine (Peptide vaccine)
Targets
folate receptor 1 (FR-alpha) (FOLR1) (antigen)
Mechanism
Immune activation, directed at folate receptor 1 (FR-alpha) (FOLR1)
Pathways
immune_activation, cytotoxic_T_lymphocyte_response
Therapy area
Oncology
Developer
Marker Therapeutics, Inc. (MRKR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02764333 Phase 2 Ovarian Cancer Completed MRKR
NCT02593227 Phase 2 Breast Cancer Completed MRKR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Breast CancerOvarian Cancer

Other drugs acting on FOLR1

ABBV-901 Phase 1 Opugotamig Olatansine Phase 2 Sofetabart Mipitecan Phase 3 Torvutatug Samrotecan Phase 1 ZW191 Phase 1

More from Marker Therapeutics

Neldaleucel Phase 1 Zedenoleucel Phase 2

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.